In 2013, Femia et al. reported that long-term treatment with the DPP4 inhibitor (sitagliptin) reduced features of colon cancer and reactive oxygen species in rats, and that the protective nature of DPP4 inhibition against colon cancer could be utilized in chemoprevention clinical trials [132]. This evidence concerns the gene DPP4 and colonic neoplasm.